Bioeconomy and biotechnology policy

The first principle

A living cell is a factory that runs at room temperature on sugar and water, and its machinery is written in DNA, so changing the DNA changes what the factory makes. Biotechnology turns this into industry: a microbe given a human gene makes insulin, a yeast given the right genes makes a dairy protein, and a bacterium can be set to turn waste carbon into a chemical. A bioeconomy is the share of an economy built on such processes, and its promise is to make medicines, food, fuels and materials with less fossil carbon and less pollution than chemistry from petroleum.

The core

How biomanufacturing works

• Cells as factories. A gene for the wanted product is placed in a host such as Escherichia coli, yeast or a mammalian cell line, the cells are grown in a steel tank called a fermenter or bioreactor, and the product is then separated and purified; human insulin made this way was the first such medicine approved, in 1982. How the gene is inserted is explained in the DNA and genetic engineering note.
• Precision fermentation uses engineered microbes to make one specific molecule, such as a milk protein, an enzyme or a flavour, while biomass fermentation grows the microbe itself as food, as in mycoprotein.
• Scale up is the hard part. A process that works in a one litre flask often fails in a ten thousand litre tank because mixing, oxygen and heat behave differently, so pilot plants that test the middle scale are where most start ups stall.
• Biologics and biosimilars. Large protein medicines such as monoclonal antibodies and vaccines are made in living cells, and a biosimilar is a close copy of a biologic whose patent has expired; because cells vary, a biosimilar cannot be identical the way a generic tablet is, so it needs more testing.

Biofoundries and engineering biology

• A biofoundry is an automated laboratory for engineering organisms. Robots, standard DNA parts and software let researchers run the design, build, test and learn cycle many times quickly: design a genetic change on a computer, build it in cells, test what the cells make, and feed the data back into the next design.
• Artificial intelligence speeds the cycle by predicting protein structures and which genetic designs will work, so fewer experiments are wasted.
• Synthetic biology is the wider field of designing new biological parts and systems.

Dimensions

• Economic. India's bioeconomy grew from about 10 billion US dollars in 2014 to about 165.7 billion dollars in 2024, roughly 4.25 per cent of gross domestic product (GDP), according to the India Bioeconomy Report 2025, and the latest government estimate puts it above 195 billion dollars, against a target of 300 billion dollars by 2030.
• Health. India supplies a large share of the world's vaccines and generic medicines, and biosimilars and cell therapies made at Indian costs can widen access at home and abroad.
• Environmental. Bio based chemicals and plastics can replace petroleum feedstocks, enzymes can cut energy use in industry, and microbes can capture carbon, though the gain depends on the source of the biomass and the energy used.
• Agricultural and rural. Biomanufacturing hubs placed near sources of biomass can create demand for crop residues and jobs outside large cities, which is why the policy favours smaller cities.
• Strategic. Dependence on imported enzymes, fermentation equipment and key drug ingredients exposed Indian industry during the Covid years, so domestic biomanufacturing is also a matter of supply security, as the indigenisation note discusses.
• Ethical and security. The same tools that make medicines can make harmful organisms, so biosafety, which protects people and the environment from accidents, and biosecurity, which guards against misuse, must grow with the industry.

In practice

Institutions and schemes

• The Department of Biotechnology (DBT), set up in 1986 under the Ministry of Science and Technology, funds research and runs autonomous institutes now grouped under the Biotechnology Research and Innovation Council (BRIC); its public sector company, the Biotechnology Industry Research Assistance Council (BIRAC), set up in 2012, funds start ups and small firms through grants, incubators and challenges.
• The BioE3 (Biotechnology for Economy, Environment and Employment) Policy, approved by the Union Cabinet on 24 August 2024, is India's first policy for high performance biomanufacturing. It names six thematic sectors: bio based chemicals and enzymes; smart proteins and functional foods; precision biotherapeutics; climate resilient agriculture; carbon capture and utilisation; and marine and space biotechnology. It builds three kinds of shared facility: biofoundries, biomanufacturing hubs in smaller cities near biomass, and Bio-AI hubs that join biological data with computing.
• Implementation so far. The National Biofoundry Network was launched on 25 August 2025, and by July 2026 the government reported more than 270 projects recommended for funding, 17 biofoundries and biomanufacturing hubs supported, 15 Bio-AI hubs recommended and BioE3 cells notified in Assam, Sikkim and Himachal Pradesh.
• The Bio-RIDE (Biotechnology Research Innovation and Entrepreneurship Development) scheme, approved in September 2024 with an outlay of Rs 9,197 crore for 2021-22 to 2025-26, merged DBT's research and industry schemes and added a new component for biomanufacturing and biofoundries.
• Data rules. The Biotech-PRIDE (Promotion of Research and Innovation through Data Exchange) Guidelines of 2021 require publicly funded biological data to be deposited in the Indian Biological Data Centre, which feeds Indian datasets into this research, as the genomics note explains.

Regulation and bioethics

• The Rules of 1989, made under the Environment (Protection) Act 1986, govern genetically engineered organisms through a ladder of committees: an Institutional Biosafety Committee in each laboratory, the Review Committee on Genetic Manipulation (RCGM) under DBT for research and small trials, and the Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment, Forest and Climate Change for large trials and release into the environment.
• Product regulators sit beside them: the Central Drugs Standard Control Organisation (CDSCO) for medicines, vaccines and biosimilars, and the Food Safety and Standards Authority of India (FSSAI) for food, including new foods such as smart proteins.
• Access and benefit sharing. The Biological Diversity Act 2002, amended in 2023, requires approval and a share of benefits when Indian biological resources are used commercially, and India is a party to the Nagoya Protocol on this subject.
• Bioethics asks who consents to the use of samples and data, who owns what is made from them, and where research must stop, such as editing heritable human genes.

Issues and way forward

• A crowded regulatory path. A product may need approvals from several committees and ministries, each with its own timelines, which deters investment; a single window with fixed timelines, of the kind long proposed for a statutory biotechnology regulator, would give certainty without lowering standards.
• Scale up finance. Grants support ideas and banks fund proven plants, but few fund the pilot and demonstration stage; shared facilities under BioE3, patient capital such as the Research, Development and Innovation fund and public procurement of Indian bio based products are the answers.
• Skills. Bioprocess engineers, fermentation technicians and data scientists for biology are scarce, so courses tied to the new hubs and apprenticeships in industry are needed.
• Feedstock and sustainability. Bio based production needs reliable biomass; using residues and waste rather than food crops keeps the bioeconomy from competing with food.
• Biosafety and biosecurity. Wider access to gene synthesis and automation raises the risk of accidents and misuse, so screening of DNA orders, laboratory audits and training in responsible research should grow with funding.
• Public trust. The GM crop debate shows that a technology can stall when the public is not consulted, so open data on safety and early public engagement should accompany new products such as smart proteins.

Common confusions

• Biofoundry and biomanufacturing hub. A biofoundry designs and tests engineered organisms at small scale, while a biomanufacturing hub scales the proven process up to pilot and commercial production.
• Biosimilar and generic. A generic is an exact chemical copy of a small molecule drug, while a biosimilar is a close but not identical copy of a protein made in living cells.
• Biosafety and biosecurity. Biosafety guards against accidental harm from organisms, while biosecurity guards against their deliberate misuse.
• GEAC and RCGM. RCGM, under DBT, clears research and small trials, while GEAC, under the Environment Ministry, decides large trials and release into the environment.
• BioE3 and Bio-RIDE. BioE3 is the policy that sets direction and sectors, while Bio-RIDE is the funding scheme through which DBT pays for research, start ups and biomanufacturing.

For the exam

• Keyword bank: bioeconomy, biomanufacturing, precision fermentation, biofoundry, design build test learn cycle, BioE3 Policy, Bio-RIDE scheme, BIRAC, biosimilar, smart proteins, scale up, biosafety and biosecurity, GEAC and RCGM, access and benefit sharing, circular bioeconomy.
• Previous year questions: Practise the previous year questions on this topic →
• Use in an answer:
  • Introduction with data: India's bioeconomy grew from about 10 billion US dollars in 2014 to more than 195 billion dollars by the latest government estimate, and the target is 300 billion dollars by 2030.
  • Introduction with a source: The BioE3 Policy approved by the Union Cabinet in August 2024 aims to make biomanufacturing a pillar of growth that serves the economy, the environment and employment together.
  • Conclusion: India has the scientists, the vaccine record and the low costs to lead in biomanufacturing; what it now needs is finance for scale up, a faster single window regulator and public trust earned through open safety data.
  • Conclusion: A bioeconomy that runs on residues rather than food crops, and on clean rather than fossil energy, can make growth and climate goals pull in the same direction.